lentiCRISPR v2 puro - CRBN (#1) Citations (2)

Originally described in: A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer.
Lier S, Sellmer A, Orben F, Heinzlmeir S, Krauss L, Schneeweis C, Hassan Z, Schneider C, Schafer A, Pongratz H, Engleitner T, Ollinger R, Kuisl A, Bassermann F, Schlag C, Kong B, Dove S, Kuster B, Rad R, Reichert M, Wirth M, Saur D, Mahboobi S, Schneider G Bioorg Chem. 2021 Nov 20:105505. doi: 10.1016/j.bioorg.2021.105505. PubMed Journal

---

Articles Citing lentiCRISPR v2 puro - CRBN (#1)

Articles
Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization. Vick EJ, Hassan A, Choi K, Bennett J, Muto T, Clough CA, Culver-Cochran AE, Hueneman K, Bolanos LC, Wunderlich M, Zhang X, McKnight C, Ceribelli M, Holland D, Klumpp-Thomas C, Greis KD, Thomas CJ, Starczynowski DT. Leukemia. 2025 Sep;39(9):2163-2173. doi: 10.1038/s41375-025-02695-3. Epub 2025 Jul 16. PubMed
Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics. Steger M, Nishiguchi G, Wu Q, Schwalb B, Shashikadze B, McGowan K, Actis M, Aggarwal A, Shi Z, Price J, Mayasundari A, Yang L, Bednarz AH, Machata S, Graef T, Bartoschek D, Demichev V, Ohmayer U, Yang J, Daub H, Rankovic Z. Nat Commun. 2025 Aug 20;16(1):7773. doi: 10.1038/s41467-025-62829-0. PubMed

If you have published an article using this material, please email us at to have your article added to this page.